I like the generic-drug business, and although Teva's debt level is certainly high, I feel that the company's legal exposure to the opioid epidemic and price inflation, as well as competitive pressures from other manufacturers, have been overestimated by the market. Finally, I consider Teva to be perhaps my most speculative stock. As of Sept. 11, FedEx has risen by about 13%, Tanger by 18%, and Teva by 31%.